Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Dapagliflozin Attenuates Na+/H+ Exchanger-1 in Cardiofibroblasts via AMPK Activation
Yumei Ye, Xiaoming Jia, Mandeep Bajaj, et al.
Cardiovascular Drugs and Therapy (2018) Vol. 32, Iss. 6, pp. 553-558
Closed Access | Times Cited: 94

Showing 1-25 of 94 citing articles:

Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors
Gary D. Lopaschuk, Subodh Verma
JACC Basic to Translational Science (2020) Vol. 5, Iss. 6, pp. 632-644
Open Access | Times Cited: 611
Critical Reanalysis of the Mechanisms Underlying the Cardiorenal Benefits of SGLT2 Inhibitors and Reaffirmation of the Nutrient Deprivation Signaling/Autophagy Hypothesis
Milton Packer
Circulation (2022) Vol. 146, Iss. 18, pp. 1383-1405
Open Access | Times Cited: 252
Empagliflozin, a sodium glucose co-transporter-2 inhibitor, alleviates atrial remodeling and improves mitochondrial function in high-fat diet/streptozotocin-induced diabetic rats
Qingmiao Shao, Lei Meng, Sharen Lee, et al.
Cardiovascular Diabetology (2019) Vol. 18, Iss. 1
Open Access | Times Cited: 233
Empagliflozin in acute myocardial infarction: the EMMY trial
Dirk von Lewinski, Ewald Kolesnik, Norbert J. Tripolt, et al.
European Heart Journal (2022) Vol. 43, Iss. 41, pp. 4421-4432
Open Access | Times Cited: 197
The Role of AMPK Activation for Cardioprotection in Doxorubicin-Induced Cardiotoxicity
Kerstin N. Timm, Damian J. Tyler
Cardiovascular Drugs and Therapy (2020) Vol. 34, Iss. 2, pp. 255-269
Open Access | Times Cited: 145
Infarct size, inflammatory burden, and admission hyperglycemia in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: a multicenter international registry
Pasquale Paolisso, Luca Bergamaschi, Gaetano Santulli, et al.
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 144
Direct cardiac effects of SGLT2 inhibitors
Sha Chen, Ruben Coronel, Markus W. Hollmann, et al.
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 107
The Cardioprotective and Anticancer Effects of SGLT2 Inhibitors
Mohamed S. Dabour, Mina Y. George, Mary R. Daniel, et al.
JACC CardioOncology (2024) Vol. 6, Iss. 2, pp. 159-182
Open Access | Times Cited: 18
Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Acute Coronary Syndrome: A Modern Cinderella?
Paschalis Karakasis, Nikolaos Fragakis, Κωνσταντίνος Κούσκουρας, et al.
Clinical Therapeutics (2024) Vol. 46, Iss. 11, pp. 841-850
Closed Access | Times Cited: 16
Direct Effects of Empagliflozin on Extracellular Matrix Remodelling in Human Cardiac Myofibroblasts: Novel Translational Clues to Explain EMPA-REG OUTCOME Results
Sean Kang, Subodh Verma, Ali Fatehi Hassanabad, et al.
Canadian Journal of Cardiology (2019) Vol. 36, Iss. 4, pp. 543-553
Closed Access | Times Cited: 140
Autophagy stimulation and intracellular sodium reduction as mediators of the cardioprotective effect of sodium–glucose cotransporter 2 inhibitors
Milton Packer
European Journal of Heart Failure (2020) Vol. 22, Iss. 4, pp. 618-628
Open Access | Times Cited: 86
The SGLT2 inhibitor Empagliflozin attenuates interleukin-17A-induced human aortic smooth muscle cell proliferation and migration by targeting TRAF3IP2/ROS/NLRP3/Caspase-1-dependent IL-1β and IL-18 secretion
Sergiy Sukhanov, Yusuke Higashi, Tadashi Yoshida, et al.
Cellular Signalling (2020) Vol. 77, pp. 109825-109825
Open Access | Times Cited: 85
Can dapagliflozin have a protective effect against COVID-19 infection? A hypothesis
Erkan Cüre, Medine Cumhur Cüre
Diabetes & Metabolic Syndrome Clinical Research & Reviews (2020) Vol. 14, Iss. 4, pp. 405-406
Open Access | Times Cited: 84
Dapagliflozin and Ticagrelor Have Additive Effects on the Attenuation of the Activation of the NLRP3 Inflammasome and the Progression of Diabetic Cardiomyopathy: an AMPK–mTOR Interplay
Huan Chen, Da T. Tran, Hsiu-Chiung Yang, et al.
Cardiovascular Drugs and Therapy (2020) Vol. 34, Iss. 4, pp. 443-461
Closed Access | Times Cited: 75
SGLT2 inhibitors reduce infarct size in reperfused ischemic heart and improve cardiac function during ischemic episodes in preclinical models
Ioanna Andreadou, Robert M. Bell, Hans Erik Bøtker, et al.
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease (2020) Vol. 1866, Iss. 7, pp. 165770-165770
Open Access | Times Cited: 73
Empagliflozin alleviates neuronal apoptosis induced by cerebral ischemia/reperfusion injury through HIF-1α/VEGF signaling pathway
Rania G. Abdel‐latif, Rehab Ahmed Rifaai, Entesar F. Amin
Archives of Pharmacal Research (2020) Vol. 43, Iss. 5, pp. 514-525
Closed Access | Times Cited: 72
Dapagliflozin: a sodium–glucose cotransporter 2 inhibitor, attenuates angiotensin II-induced cardiac fibrotic remodeling by regulating TGFβ1/Smad signaling
Yuze Zhang, Xiaoyan Lin, Yong Chu, et al.
Cardiovascular Diabetology (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 61
SGLT2 inhibitor dapagliflozin attenuates cardiac fibrosis and inflammation by reverting the HIF ‐2α signaling pathway in arrhythmogenic cardiomyopathy
Zhe Yang, Tengling Li, Jianzhong Xian, et al.
The FASEB Journal (2022) Vol. 36, Iss. 7
Open Access | Times Cited: 52
Cardioprotection by selective SGLT-2 inhibitors in a non-diabetic mouse model of myocardial ischemia/reperfusion injury: a class or a drug effect?
Panagiota Nikolaou, N Mylonas, Manousos Makridakis, et al.
Basic Research in Cardiology (2022) Vol. 117, Iss. 1
Closed Access | Times Cited: 43
Sodium-Glucose Cotransporter 2 Inhibitors and Cardiac Remodeling
Husam M. Salah, Subodh Verma, Carlos G. Santos‐Gallego, et al.
Journal of Cardiovascular Translational Research (2022) Vol. 15, Iss. 5, pp. 944-956
Closed Access | Times Cited: 40
Mechanisms of benefits of sodium-glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction
Arjun Pandey, Deepak L. Bhatt, Avinash Pandey, et al.
European Heart Journal (2023) Vol. 44, Iss. 37, pp. 3640-3651
Closed Access | Times Cited: 35
Empagliflozin suppressed cardiac fibrogenesis through sodium-hydrogen exchanger inhibition and modulation of the calcium homeostasis
Cheng‐Chih Chung, Yung‐Kuo Lin, Yao‐Chang Chen, et al.
Cardiovascular Diabetology (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 25
Empagliflozin mitigates cardiac hypertrophy through cardiac RSK/NHE-1 inhibition
Sha Chen, Kenneth Overberg, Zakiya Ghouse, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 174, pp. 116477-116477
Open Access | Times Cited: 9
Empagliflozin prevents heart failure through inhibition of the NHE1-NO pathway, independent of SGLT2
Sha Chen, Qian Wang, Diane Bakker, et al.
Basic Research in Cardiology (2024) Vol. 119, Iss. 5, pp. 751-772
Open Access | Times Cited: 8
Danuglipron Ameliorates Pressure Overload‐Induced Cardiac Remodelling Through the AMPK Pathway
Pan Wang, Zhen Guo, Chun‐Yan Kong, et al.
Journal of Cellular and Molecular Medicine (2025) Vol. 29, Iss. 5
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top